Dr. Reddy’s Laboratories announced a significant interim development regarding its Semaglutide-containing products on March 10, 2026. The Delhi High Court Division Bench upheld a previous order permitting the company to manufacture Semaglutide in India. Crucially, this order allows the company to export the product to international markets where competitor Novo Nordisk does not hold existing patent registrations. The matter remains under judicial review.
High Court Decision on Semaglutide Manufacturing
Dr. Reddy’s Laboratories issued a clarification on March 10, 2026, following media reports regarding a ruling by the Delhi High Court concerning its Semaglutide products. This clarification addresses an ongoing legal proceeding involving the Danish drug maker, Novo Nordisk.
The Division Bench of the Delhi High Court, through its judgment dated March 09, 2026, has confirmed and upheld the ruling made by the previous Single-Judge Bench. This legal victory permits Dr. Reddy’s to proceed with the manufacture of Semaglutide within India.
Key Outcome: Export Permission Granted
The most critical aspect of the ruling is the refusal by the Division Bench to grant an interim injunction sought by Novo Nordisk. Consequently, Dr. Reddy’s is permitted to export Semaglutide-containing products to all countries where Novo Nordisk currently does not possess patent protection for the related compounds. This allows the company to commercialize its product in specific international territories.
Current Status of the Matter
The company officially confirmed that while the legal dispute continues, the matter remains sub-judice. At this current stage, there is no further material event or information that requires an immediate broader regulatory disclosure beyond this clarification.
Source: BSE
